Carotuximab, referred to as TRC105 or DE-122, represents a novel antibody-drug conjugate ADC currently evaluated for treating various cancerous diseases. This specific molecule targets a unique antigen, found on https://ihannauwfw477390.wikiannouncement.com/10421888/carotuximab_trc105_de_122_a_deep_dive